Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Pipeline Review, H2 2017

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Pipeline Review, H2 2017


  • Products Id :- GMDHC1018TDB
  • |
  • Pages: 67
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Placenta Growth Factor-Pipeline Review, H2 2017'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

The report 'Placenta Growth Factor-Pipeline Review, H2 2017' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 3 and 3 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Diabetic Retinopathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion and Retinopathy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Overview 6

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Therapeutics Assessment 13

Assessment by Mechanism of Action 13

Assessment by Route of Administration 14

Assessment by Molecule Type 16

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Companies Involved in Therapeutics Development 18

Alteogen Inc 18

Chengdu Kanghong Pharmaceuticals Group Co Ltd 18

Formycon AG 18

Lupin Ltd 19

Regeneron Pharmaceuticals Inc 20

ThromboGenics NV 20

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Drug Profiles 22

(aflibercept + nesvacumab)-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

aflibercept-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

aflibercept biosimilar-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

aflibercept biosimilar-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

aflibercept biosimilar-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

aflibercept SR-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

conbercept-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

SL-186-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

SL-188-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

THR-317-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ziv-aflibercept-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Dormant Products 52

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Discontinued Products 53

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Product Development Milestones 54

Featured News & Press Releases 54

Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017 54

May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 55

May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017 56

Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 57

Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 58

Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS 58

Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance 59

May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 60

May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma 61

Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 62

Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 62

Feb 29, 2016: Formycon discloses details on second pipeline product-FYB203 is a biosimilar for Eylea (aflibercept) 63

Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 64

Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 64

Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 65

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Routes of Administration, H2 2017 14

Number of Products by Stage and Routes of Administration, H2 2017 14

Number of Products by Molecule Types, H2 2017 16

Number of Products by Stage and Molecule Types, H2 2017 16

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 17

Pipeline by Alteogen Inc, H2 2017 18

Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 18

Pipeline by Formycon AG, H2 2017 19

Pipeline by Lupin Ltd, H2 2017 19

Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 20

Pipeline by ThromboGenics NV, H2 2017 21

Dormant Projects, H2 2017 52

Discontinued Products, H2 2017 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alteogen Inc

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Formycon AG

Lupin Ltd

Regeneron Pharmaceuticals Inc

ThromboGenics NV

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Therapeutic Products under Development, Key Players in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Therapeutics, Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Pipeline Overview, Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Pipeline, Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Pipeline Assessment

select a license
Single User License
USD 3500 INR 241430
Site License
USD 7000 INR 482860
Corporate User License
USD 10500 INR 724290

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com